![Patrick Yeramian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Yeramian
Corporate Officer/Principal bei
Dlx Therapeutics L L C
Profil
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Aktive Positionen von Patrick Yeramian
| Unternehmen | Position | Beginn |
|---|---|---|
Dlx Therapeutics L L C | Corporate Officer/Principal | 01.01.2018 |
Ehemalige bekannte Positionen von Patrick Yeramian
| Unternehmen | Position | Ende |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 28.11.2023 |
| BIOVIE INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2019 |
| MARKER THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 |
Tapimmune, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 |
Ausbildung von Patrick Yeramian
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
15
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Develops and researches immunological products | Health Technology |
Marker Therapeutics, Inc.
 Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universite Paris Est Creteil Val De Marne
 Universite Paris Est Creteil Val De Marne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
G.D. Searle LLC | |
Rutgers Business School
 Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
Amylyx Pharmaceuticals, Inc.
 Amylyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products to cure neurodegenerative diseases | Health Technology |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Commercial Services |
Dlx Therapeutics L L C | |
Tapimmune, Inc. |
